Background: Survival varies widely among different neurodegenerative diseases. Data on the role of the Mini Mental State Examination (MMSE) and apolipoprotein E (APOE) in survival are sparse except for Alzheimer’s disease (AD). Methods: We studied mortality of 3,581 patients in an academic clinic from 1993 to 2004. Average follow-up was 4.1 years. We studied patients with amyotrophic lateral sclerosis (ALS) (n = 174), possible AD (n = 206), probable AD (n = 1,175), Parkinson’s disease (PD) (n = 661), mild cognitive impairment (MCI) (n = 357), frontotemporal dementia (FTD) (n = 94), Lewy body disease (LBD) (n = 64), and controls (n = 850). We compared patients’ mortality to the US population and to controls. Results: Mortality ranged from 7% for controls to 58% for ALS patients. The median survival times from initial visit for PD, FTD, probable AD, possible AD, LBD, and ALS were 8.9, 7.0, 5.9, 5.6, 5.3, and 2.7 years, respectively. Mortality rate ratios comparing each disease to controls were 39.43, 7.25, 3.70, 3.51, 2.47, 2.73, and 1.61 for ALS, FTD, LBD, PD, probable AD, possible AD, and MCI, respectively. A lower initial MMSE score was associated with higher mortality for probable AD, PD, and MCI, while APOE4 predicted mortality for PD and LBD. Non-whites had 20% lower mortality rates than whites for all dementias combined, adjusting for education. Conclusions: All neurologic diseases, including MCI, had increased mortality versus controls. A lower MMSE score and APOE4 presence predicted higher mortality for some patient groups.
© 2010 S. Karger AG, Basel
- Neurodegenerative disease
- Apolipoprotein E4
- Mini Mental State Examination
- Wolfson C, Wolfson DB, Asgharian M, M’Lan CE, Ostbye T, Rockwood K, Hogan DB; Clinical Progression of Dementia Study Group: A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111–1116.
- Villareal DT, Grant E, Miller JP, Storandt M, McKeel DW, Morris JC: Clinical outcomes of possible versus probable Alzheimer’s disease. Neurology 2003;61:661–667.
- Singer RB: Mortality derived from 5-year survival in patients with Alzheimer disease. J Insur Med 2005;37:264–271.
- Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W: Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 2005;19:178–183.
- Barclay LL, Zemcov A, Blass JP, Sansone J: Survival in Alzheimer’s disease and vascular dementias. Neurology 1985;35:834–840.
- Walsh JS, Welch HG, Larson EB: Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990;113:429–434.
- Brookmeyer R, Corrada MM, Curriero FC, Kawas C: Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764–1767.
- Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA: Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004;140:501–509.
- Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y: Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology 2008;71:1489–1495.
- Mehta KM, Yaffe K, Pérez-Stable EJ, Stewart A, Barnes D, Kurland BF, Miller BL: Race/ethnic differences in AD survival in US Alzheimer’s Disease Centers. Neurology 2008;70:1163–1170.
- Claus JJ, van Gool WA, Teunisse S, Walstra GJ, Kwa VI, Hijdra A, Verbeeten B Jr, Koelman JH, Bour LJ, Ongerboer De Visser BW: Predicting survival in patients with early Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:284–293.
- Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST: Research evaluation and diagnosis of possible Alzheimer’s disease over the last two decades. Part 2. Neurology 2000;55:1863–1869.
- Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC: Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol 1997;54:878–885.
- Mandrioli J, Faglioni P, Nichelli P, Sola P: Amyotrophic lateral sclerosis: prognostic indicators of survival. Amyotroph Lateral Scler 2006;7:211–220.
- Czaplinski A, Yen AA, Appel SH: Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006;253:1428–1436.
- Forbes RB, Colville S, Swingler RJ; Scottish ALS/MND Register: The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing 2004;33:131–134.
- Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G: Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:208–212.
- Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA: Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 2003;60:91–96.
- Fall PA, Saleh A, Fredrickson M, Olsson JE, Granérus AK: Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord 2003;18:1312–1316.
- Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group: Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64:87–93.
- D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G, Savettieri G: Long-term survival of Parkinson’s disease: a population-based study. J Neurol 2006;253:33–37.
- Jellinger KA, Wenning GK, Seppi K: Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428–430.
- Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A: Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 2006;21:1002–1007.
- Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G: Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008;70:1423–1430.
- Herlofson K, Lie SA, Arsland D, Larsen JP: Mortality and Parkinson disease: a community-based study. Neurology 2004;62:937–942.
- Hughes TA, Ross HF, Mindham RH, Spokes EG: Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118–123.
- Guehne U, Angermeyer MC, Riedel-Heller S: Is mortality increased in mildly cognitively impaired individuals? A systematic literature review. Dement Geriatr Cogn Disord 2006;21:403–410.
- Hunderfund AL, Roberts RO, Slusser TC, Leibson CL, Geda YE, Ivnik RJ, Tangalos EG, Petersen RC: Mortality in amnestic mild cognitive impairment: a prospective community study. Neurology 2006;67:1764–1768.
- Guehne U, Luck T, Busse A, Angermeyer MC, Riedel-Heller SG: Mortality in individuals with mild cognitive impairment. Results of the Leipzig Longitudinal Study of the Aged. Neuroepidemiology 2007;29:226–234.
- Lee HB, Kasper JD, Shore AD, Yokley JL, Black BS, Rabins PV: Level of cognitive impairment predicts mortality in high-risk community samples: the memory and medical care study. J Neuropsychiatry Clin Neurosci 2006;18:543–546.
- Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D: Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005;65:397–403.
- Hodges JR, Davies R, Xuereb J, Kril J, Halliday G: Survival in frontotemporal dementia. Neurology 2003;61:349–354.
- Pasquier F, Richard F, Lebert F: Natural history of frontotemporal dementia: comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;17:253–257.
- Roberson ED, Hesse JH, Rose KD, Slama H, Johnson JK, Yaffe K, Forman MS, Miller CA, Trojanowski JQ, Kramer JH, Miller BL: Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 2005;65:719–725.
- Bonsignore M, Heun R: Mortality in Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;15:231–236.
- Carcaillon L, Pérès K, Péré JJ, Helmer C, Orgogozo JM, Dartigues JF: Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community. Dement Geriatr Cogn Disord 2007;23:439–445.
- Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF; REAL.fr Group: Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;23:168–174.
- Wilson RS, Li Y, Aggarwal NT, McCann JJ, Gilley DW, Bienias JL, Barnes LL, Evans DA: Cognitive decline and survival in Alzheimer’s disease. Int J Geriatr Psychiatry 2006;21:356–362.
- Hui JS, Wilson RS, Bennett DA, Bienias JL, Gilley DW, Evans DA: Rate of cognitive decline and mortality in Alzheimer’s disease. Neurology 2003;61:1356–1361.
- Dal Forno G, Carson KA, Brookmeyer R, Troncoso J, Kawas CH, Brandt J: APOE genotype and survival in men and women with Alzheimer’s disease. Neurology 2002;58:1045–1050.
- Tilvis RS, Strandberg TE, Juva K: Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. J Am Geriatr Soc 1998;46:712–715.
- Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, Sulkava R: APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412–415.
- Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, Hofman A, Stijnen T, van Duijn CM: Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study. J Neurol 1999;246:304–308.
- Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ: Parkinson’s disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294–299.
- Fernandez HH, Lapane KL: Predictors of mortality among nursing home residents with a diagnosis of Parkinson’s disease. Med Sci Monit 2002;8:CR241–CR246.
- Cowper DC, Kubal JD, Maynard C, Hynes DM: A primer and comparative review of major US mortality databases. Ann Epidemiol 2002;12:462–468.
- Binetti G, Locascio JJ, Corkin S, Vonsattel JP, Growdon JH: Differences between Pick disease and Alzheimer disease in clinical appearance and rate of cognitive decline. Arch Neurol 2000;57:225–232.
- Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN: Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001;57:1756–1763.
- Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD: Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 2007;165:8874–8881.
- Steenland K, Henley J, Thun M: All cause and cause-specific mortality by educational status in two million people in two ACS cohorts. Am J Epidemiol 2002;156:11–21.
- de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM: Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62:1265–1269.
- Feldman B, Chapman J, Korczyn AD: Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 2006;113:14–17.
- Steenland K, Macneil J, Vega I, Levey A: Recent mortality patterns in Alzheimer’s Disease. Alzheimer Dis Assoc Disord 2009;23:165–170.
- Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49–56.
- Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;60:185–189.
- Fillenbaum GG, Heyman A, Huber MS, Woodbury MA, Leiss J, Schmader KE, Bohannon A, Trapp-Moen B: The prevalence and 3-year incidence of dementia in older Black and White community residents. J Clin Epidemiol 1998;51:587–595.
Rollins School of Public Health, Emory University
1518 Clifton Road NE
Atlanta, GA 30322 (USA)
Tel. +1 404 712 8277, E-Mail email@example.com
Received: November 2, 2009
Accepted after revision: January 26, 2010
Published online: April 8, 2010
Number of Print Pages : 8
Number of Figures : 1, Number of Tables : 6, Number of References : 56
Vol. 35, No. 1, Year 2010 (Cover Date: July 2010)
Journal Editor: Feigin V.L. (Auckland)
ISSN: 0251-5350 (Print), eISSN: 1423-0208 (Online)
For additional information: http://www.karger.com/NED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.